Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands... Show more
Emerson Electric (EMR) has demonstrated resilience in recent trading sessions, posting a roughly 10% gain amid volatile market conditions. The stock trades around $137 within a 52-week range of $106.53 to $165.15, reflecting year-to-date gains of nearly 4% and over 30% annually. With a market cap exceeding $77 billion, P/E ratio near 34, and trailing EPS of $4.08, EMR remains positioned in the industrial automation space. Investors are focused on the broader cycle of technology-driven demand in manufacturing and infrastructure, balancing growth prospects against valuation concerns.
Tickeron's Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from its library of 351 bots, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies including trend trading, swing trades, dip buying, and paired long/short positions, with timeframes from 5-minute to hourly charts. Performance highlights include annualized returns ranging from 24% to 163%, win rates of 51% to 88%, and portfolios covering 3 to 18 tickers per bot, spanning sectors like semiconductors, industrials, and energy. Virtual agents incorporate risk management with customizable take-profit (e.g., 3%) and stop-loss (e.g., 2%) levels, while signal and brokerage agents offer real-time execution. Tailored for current market volatility, these tools suit various risk appetites—explore them to potentially enhance your trading edge.
In the past 30 days, Emerson Electric (EMR) stock has navigated mixed price action, including a notable 10% rally tied to optimism around industrial automation, interspersed with sessions where shares underperformed broader market gains. This volatility reflects investor anticipation for the Q2 FY2026 earnings release on May 5, where Wall Street anticipates EPS of $1.55—up 0.5% in consensus estimates over recent weeks—and revenue of $4.6 billion. Positive revisions signal confidence in ongoing momentum from Q1 results, where underlying orders grew robustly.
Analyst activity has provided further direction. Early April saw Jefferies upgrade EMR to Buy, highlighting accelerating earnings into FY2027 on strong order backlog and automation tailwinds. Barclays maintained a price target of $140 around the same time, while overall consensus from 23 analysts rates the stock a Hold (1 Sell, 10 Hold, 12 Buy), with an average target near $157. These views underscore balanced sentiment, cautious on near-term valuation (P/E over 33) despite growth prospects.
Macro factors, including persistent demand for AI-enabled automation solutions and industrial infrastructure, have bolstered the recent uptick, contrasting with occasional pullbacks amid insider sales and broader market rotations away from industrials. No major M&A (mergers and acquisitions) or regulatory news emerged, keeping focus on operational execution and the earnings catalyst. Price dips, like one where EMR fell over 2% against market advances, highlighted sensitivity to short-term sentiment shifts.
For fiscal 2026, Emerson Electric maintains raised guidance of adjusted EPS $6.40-$6.55, implying 8-9% growth, with total sales up 5.5% (4% underlying) fueled by margin expansion and robust demand in automation. The company plans ~$2.2 billion in shareholder returns via $1 billion repurchases and dividends, pivoting capital allocation post-strategic shifts.
Investors should track industrial IoT adoption, AI integration in products, and order trends in key segments like AspenTech partnerships. Risks include supply chain pressures, economic slowdowns impacting capex (capital expenditures), and competition from peers in electrification. Opportunities lie in data center builds and resilient North American manufacturing. Regulatory scrutiny on tech and industrials, plus free cash flow growth to $3.5 billion+, will shape positioning through the year.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
The 50-day moving average for EMR moved above the 200-day moving average on May 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on June 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in of 333 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 275 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EMR as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
EMR moved below its 50-day moving average on June 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.782) is normal, around the industry mean (6.078). P/E Ratio (31.738) is within average values for comparable stocks, (49.222). Projected Growth (PEG Ratio) (1.918) is also within normal values, averaging (1.975). Dividend Yield (0.016) settles around the average of (0.019) among similar stocks. P/S Ratio (4.225) is also within normal values, averaging (138.995).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery